For decades, Parkinson’s disease has been framed as a straightforward story about dying brain cells and dwindling dopamine. A ...

A research team led by McGill University has taken a close look at a long-standing idea about Parkinson’s disease and found ...

A new study shows dopamine isn’t the brain’s movement “gas pedal” after all. Instead of setting speed or strength, it quietly ...

As people live longer, age-related brain diseases like Alzheimer’s and Parkinson’s are becoming more common. These conditions happen when certain proteins in the brain fold the wrong way and build up ...

An "exciting" new Parkinson's disease drug promises to not only treat but to cure the condition at its root cause. Early clinical trials have shown that the drug, which works by using the patient's ...

A McGill-led study is challenging a popular theory about how dopamine drives movement, a discovery that could shift how ...

Parkinson’s disease (PD) is a growing global health challenge, affecting millions worldwide and imposing significant burdens ...

Parkinson’s disease affects over 10 million people globally, with incidence increasing after age 60. Dopamine-producing neuron loss leads to both motor and non-motor symptoms, including tremors, sleep ...

Cell and gene therapies account for 20% of pipeline Parkinson's therapy bemdaneprocel in Phase 3 trial Pharma success urgently needed, says fund manager FRANKFURT, Sept 25 (Reuters) - Bayer's ...

Enrollment will begin in January 2026Participants will be treated with buntanetap for 36 monthsThe study aims to enroll 500 ...